# Tolvaptan

## Samsca 15mg

##### 臨採

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OSAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Indications        | Clinically significant hypervolemic & euvolemic hyponatremia including patients w/ heart failure & syndrome of inappropriate antidiuretic hormone (SIADH).                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Adult: Initial， 15 mg QD; may increase to 30 mg QD， after at least 24 hours， to maximum of 60 mg QD; do not administer for more than 30 days. Patient should be hospitalized for initiation or reinitiation of tolvaptan therapy to evaluate therapeutic response and avoid too rapid correction of hyponatremia. Serum sodium levels should be monitored for prevention of too rapid correction of hyponatremia. (Correction of hyponatremia < 10-12 mEq/L in 24 hours， and < 18 mEq/L in 48 hours) |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Urgent need to raise serum Na acutely; inability to sense or appropriately respond to thirst; hypovolemic hyponatremia; strong CYP3A inhibitors (eg clarithromycin， ketoconazole， itraconazole， ritonavir， indinavir， nelfinavir， saquinavir， nefazodone & telithromycin); anuric patients.                                                                                                                                                                                                       |
| Adverse Effects    | Thirst， dry mouth， pollakiuria or polyuria， asthenia， constipation， hyperglycemia， pyrexia & anorexia.                                                                                                                                                                                                                                                                                                                                                                                             |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

